A detailed history of E Fund Management Co., Ltd. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 2,863 shares of MDGL stock, worth $899,096. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,863
Previous 2,212 29.43%
Holding current value
$899,096
Previous $619,000 1.94%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$212.22 - $292.96 $138,155 - $190,716
651 Added 29.43%
2,863 $607,000
Q2 2024

Aug 12, 2024

BUY
$193.33 - $291.99 $99,371 - $150,082
514 Added 30.27%
2,212 $619,000
Q1 2024

May 13, 2024

SELL
$171.37 - $283.23 $104,192 - $172,203
-608 Reduced 26.37%
1,698 $453,000
Q4 2023

Feb 06, 2024

SELL
$120.4 - $237.13 $2,528 - $4,979
-21 Reduced 0.9%
2,306 $533,000
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $94,049 - $145,402
644 Added 38.27%
2,327 $340,000
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $17,125 - $26,208
84 Added 5.25%
1,683 $389,000
Q1 2023

May 11, 2023

SELL
$231.06 - $307.08 $908,758 - $1.21 Million
-3,933 Reduced 71.1%
1,599 $387,000
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $58,039 - $294,760
994 Added 21.9%
5,532 $1.61 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $58,631 - $76,965
968 Added 27.11%
4,538 $295,000
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $72,433 - $125,049
1,248 Added 53.75%
3,570 $256,000
Q1 2022

May 12, 2022

BUY
$55.89 - $101.89 $64,049 - $116,765
1,146 Added 97.45%
2,322 $228,000
Q1 2021

May 12, 2021

BUY
$108.54 - $125.2 $127,643 - $147,235
1,176 New
1,176 $137,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.37B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.